Alvotech
ALVODrugs in Pipeline
7
Phase 3 Programs
7
Upcoming Catalysts
3
Next Catalyst
Aug 12, 2026
7dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
ALVO Earnings Report
EPS Est: $-0.05 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Adalimumab
Plaque Psoriasis
AVT05 (proposed biosimilar to golimumab)
Rheumatoid Arthritis
AVT03
Osteoporosis, Postmenopausal
Stelara
Psoriasis
Adalimumab originator
Plaque Psoriasis
AVT06 (proposed aflibercept biosimilar)
Neovascular (Wet) AMD
AVT29 (proposed aflibercept HD biosimilar)
Diabetic Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Adalimumab | Phase 3 | Plaque Psoriasis | - | - |
AVT05 (proposed biosimilar to golimumab) | Phase 3 | Rheumatoid Arthritis | - | - |
AVT03 | Phase 3 | Osteoporosis, Postmenopausal | - | - |
Stelara | Phase 3 | Psoriasis | - | - |
Adalimumab originator | Phase 3 | Plaque Psoriasis | - | - |
AVT06 (proposed aflibercept biosimilar) | Phase 3 | Neovascular (Wet) AMD | - | - |
AVT29 (proposed aflibercept HD biosimilar) | Phase 3 | Diabetic Macular Edema | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Alvotech's drug pipeline?→
CatalystAlert tracks 7 drug candidates in Alvotech's (ALVO) pipeline across Phase 3. Its lead program is Adalimumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alvotech's next FDA catalyst?→
Alvotech's (ALVO) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALVO biotech catalysts?→
Add ALVO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alvotech's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.